Laura E. Niklason - Aug 17, 2023 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
President, CEO and Director, Director
Signature
/s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
Stock symbol
HUMA
Transactions as of
Aug 17, 2023
Transactions value $
-$6,378,837
Form type
4
Date filed
8/21/2023, 06:07 PM
Previous filing
Jun 16, 2023
Next filing
Sep 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HUMA Common Stock Sale -$2.1M -570K -5.71% $3.68 9.42M Aug 17, 2023 By Ayabudge LLC F1, F2
transaction HUMA Common Stock Sale -$2.24M -627K -6.66% $3.57 8.79M Aug 18, 2023 By Ayabudge LLC F1, F3
transaction HUMA Common Stock Sale -$2.04M -602K -6.85% $3.39 8.19M Aug 21, 2023 By Ayabudge LLC F1, F4
holding HUMA Common Stock 1.27M Aug 17, 2023 Direct
holding HUMA Common Stock 510K Aug 17, 2023 By spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.
F2 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.50 to $4.13. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.50 to $3.75. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.22 to $3.80. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.